I-BET151
Cat. No.：YN310211
CAS No. ：1300031-49-5
| 产品名称: | I-BET151 |
| CAS No.: | 1300031-49-5 |
| Chemical Name: | 7,3,5-dimethyl-4-isoxazolyl-1,3-dihydro-8-methoxy-1-[1R-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one |
| Synonyms: | GSK1210151A |
| 分子量: | 415.44 |
| 分子式: | C₂₃H₂₁N₅O₃ |
| SMILES: | C[C@@H](N1C(C(C=C(OC)C(C2=C(C)ON=C2C)=C3)=C3N=C4)=C4NC1=O)C5=CC=CC=N5 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | I-BET151 是一种 BET溴结构域 (BET bromodomain) 抑制剂，抑制BRD4，BRD2和BRD3的pIC50分别为 6.1，6.3 和 6.6。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Gallenkamp, D., Gelato, K.A., Haendler, B., et al.Bromodomains and their pharmacological inhibitorsChem. Med. Chem.9(3),438-464(2014)
Kline, T.B., Benington, F., Morin, R.D., et al.Structure-activity relationships for hallucinogenic N,N-dialkyltryptamines: Photoelectron spectra and serotonin receptor affinities of methylthio and methylenedioxy derivativesJ. Med. Chem.25(11),1381-1383(1982)
Vidler, L.R., Brown, N., Knapp, S., et al.Druggability analysis and structural classification of bromodomain acetyl-lysine binding sitesJ. Med. Chem.55(17),7346-7359(2012)
Hewings, D.S., Fedorov, O., Filippakopoulos, P., et al.Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligandsJ. Med. Chem.56(8),3217-3227(2013)
Dawson, M.A., Kouzarides, T., and Huntly, B.J.Targeting epigenetic readers in cancerN. Engl. J. Med.367(7),647-657(2012)
Dawson, M.A., Prinjha, R.K., Dittmann, A., et al.Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature478,529-533(2011)
